Pharma & Biopharma

Regeneron bispecific approved for myeloma; Concentra to buy IGM

By Newsroom
0 Min Read


Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.



Source link

Share This Article

HOT NEWS

Treatments to help utilities prepare for PFAS water regulations 

Environmental Science

Issue 84: Thermal Management Materials

Issue 84, August-September 2025 In this issue: In-depth analysis of the market for carbon nanomaterials…

تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك

California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…

Arab Newswire Provides Press Release Distribution in Arabic

Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…

YOU MAY ALSO LIKE

Insilico Medicine Raises More Than US$290 Million in Hong Kong’s Largest Biotech IPO of 2025

  News AI-driven drug discovery company Insilico Medicine raised approximately HKD 2.28 billion (more than US$290 million) in its initial public…

Pharma & Biopharma

$1B AI Drug Discovery Startup Xaira Therapeutics Appoints Foundation Model Expert Bo Wang as Head of Biomedical AI

Xaira Therapeutics, an AI-driven biotech launched in April 2024 with over $1 billion in funding, has appointed Dr. Bo Wang…

Pharma & Biopharma

Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain

  News Novo Nordisk has entered a strategic partnership with OpenAI to integrate AI systems across its research, manufacturing, and commercial…

Pharma & Biopharma

MIT study finds that the probability of clinical trial success is nearly 40% higher than previously thought

NIH Clinical Center On December 7, 2017 we published an article on this blog entitled ”Improving Candidate Selection: Translating Molecules…

Pharma & Biopharma